News
Akeso and CStone secure China clearances for next-generation...
Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.
News
Akiram, ITM sign Lutetium-177 supply agreement
Akiram & ITM sign supply agreement for Lutetium-177 to support development of targeted antibody-radionuclide conjugate AKIR001 in solid tumours.
News
AstraZeneca’s volrustomig hits Phase 3 setback in lung cance...
In another blow to its late-stage pipeline, AstraZeneca has pulled the plug on a phase 3 trial of its lung cancer treatment volrustomig.
News
BMS bags first approval for myeloma CELMoD Zenbexus
Bristol Myers Squibb's CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma.
News
FDA cites 'significant concerns' with ADC lymphoma trial
ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
